Humira: Clinical Trial Information for Rheumatoid Arthritis and Crohn’s Disease

Humira: Clinical Trial Information for Rheumatoid Arthritis and Crohn’s Disease


Hello and welcome to “VideoScript”, presented
by Drugs.com. Today in the second of three presentations,
we continue reviewing Humira, a commonly used medication in the class of drugs known as
TNF blockers. Humira is also often referred to as a biological
response modifier. We will review some of the rheumatoid arthritis
and Crohn’s disease clinical trial information for Humira. In clinical studies of Humira in early but
aggressive rheumatoid arthritis, roughly 6 out of every 10 patients improved by at least
50 percent after one year. These patients were also taking methotrexate,
another drug commonly used in rheumatoid arthritis. More patients who combined methotrexate with
Humira had a better response than those who used methotrexate alone. Studies with Humira have also shown that joint
damage, pain and overall daily function are dramatically improved in patients with rheumatoid
arthritis. The progressive destruction of the joints can be slowed or halted. Patients with Crohn’s disease are seeking
relief from symptoms such as stomach pain, diarrhea, fatigue, and weight loss. Placebo-controlled
studies with Humira showed that more than 50 percent of patients saw symptom relief
at 4 weeks of treatment. A significant portion of these patients, over 20 to 30 percent,
also went into remission from disease activity, meaning their signs and symptoms of Crohn’s
disease improved. Treatment of Crohn’s disease increases the
chances of staying in remission. A significant portion of patients were able
to stay in clinical remission at 6 months and at 1 year. Thank you for joining us at Drugs.com for
a brief review of Humira. Please refer to our patient and professional information,
drug interaction checker, and additional tools on Drugs.com. Patients with a concern about the use of Humira
should consult with their health care provider. Visit www.drugs.com/Humira for more information

Leave a Reply

Your email address will not be published. Required fields are marked *